Literature DB >> 16443704

Is EGFR expression important in non-small cell lung cancer?

S M Lee.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16443704      PMCID： PMC2104566          DOI： 10.1136/thx.2005.047936

Source DB:  PubMed          Journal:  Thorax        ISSN： 0040-6376            Impact factor:   9.139


× No keyword cloud information.
  11 in total

1.  EGFR mutation and resistance of non-small-cell lung cancer to gefitinib.

Authors:  Susumu Kobayashi; Titus J Boggon; Tajhal Dayaram; Pasi A Jänne; Olivier Kocher; Matthew Meyerson; Bruce E Johnson; Michael J Eck; Daniel G Tenen; Balázs Halmos
Journal:  N Engl J Med       Date:  2005-02-24       Impact factor: 91.245

2.  Erlotinib in previously treated non-small-cell lung cancer.

Authors:  Frances A Shepherd; José Rodrigues Pereira; Tudor Ciuleanu; Eng Huat Tan; Vera Hirsh; Sumitra Thongprasert; Daniel Campos; Savitree Maoleekoonpiroj; Michael Smylie; Renato Martins; Maximiliano van Kooten; Mircea Dediu; Brian Findlay; Dongsheng Tu; Dianne Johnston; Andrea Bezjak; Gary Clark; Pedro Santabárbara; Lesley Seymour
Journal:  N Engl J Med       Date:  2005-07-14       Impact factor: 91.245

3.  Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer.

Authors:  Federico Cappuzzo; Fred R Hirsch; Elisa Rossi; Stefania Bartolini; Giovanni L Ceresoli; Lynne Bemis; Jerry Haney; Samir Witta; Kathleen Danenberg; Irene Domenichini; Vienna Ludovini; Elisabetta Magrini; Vanesa Gregorc; Claudio Doglioni; Angelo Sidoni; Maurizio Tonato; Wilbur A Franklin; Lucio Crino; Paul A Bunn; Marileila Varella-Garcia
Journal:  J Natl Cancer Inst       Date:  2005-05-04       Impact factor: 13.506

4.  Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers.

Authors:  Hisayuki Shigematsu; Li Lin; Takao Takahashi; Masaharu Nomura; Makoto Suzuki; Ignacio I Wistuba; Kwun M Fong; Huei Lee; Shinichi Toyooka; Nobuyoshi Shimizu; Takehiko Fujisawa; Ziding Feng; Jack A Roth; Joachim Herz; John D Minna; Adi F Gazdar
Journal:  J Natl Cancer Inst       Date:  2005-03-02       Impact factor: 13.506

5.  EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib.

Authors:  William Pao; Vincent Miller; Maureen Zakowski; Jennifer Doherty; Katerina Politi; Inderpal Sarkaria; Bhuvanesh Singh; Robert Heelan; Valerie Rusch; Lucinda Fulton; Elaine Mardis; Doris Kupfer; Richard Wilson; Mark Kris; Harold Varmus
Journal:  Proc Natl Acad Sci U S A       Date:  2004-08-25       Impact factor: 11.205

6.  EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy.

Authors:  J Guillermo Paez; Pasi A Jänne; Jeffrey C Lee; Sean Tracy; Heidi Greulich; Stacey Gabriel; Paula Herman; Frederic J Kaye; Neal Lindeman; Titus J Boggon; Katsuhiko Naoki; Hidefumi Sasaki; Yoshitaka Fujii; Michael J Eck; William R Sellers; Bruce E Johnson; Matthew Meyerson
Journal:  Science       Date:  2004-04-29       Impact factor: 47.728

7.  Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib.

Authors:  Thomas J Lynch; Daphne W Bell; Raffaella Sordella; Sarada Gurubhagavatula; Ross A Okimoto; Brian W Brannigan; Patricia L Harris; Sara M Haserlat; Jeffrey G Supko; Frank G Haluska; David N Louis; David C Christiani; Jeff Settleman; Daniel A Haber
Journal:  N Engl J Med       Date:  2004-04-29       Impact factor: 91.245

8.  Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial.

Authors:  Mark G Kris; Ronald B Natale; Roy S Herbst; Thomas J Lynch; Diane Prager; Chandra P Belani; Joan H Schiller; Karen Kelly; Harris Spiridonidis; Alan Sandler; Kathy S Albain; David Cella; Michael K Wolf; Steven D Averbuch; Judith J Ochs; Andrea C Kay
Journal:  JAMA       Date:  2003-10-22       Impact factor: 56.272

9.  Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected].

Authors:  Masahiro Fukuoka; Seiji Yano; Giuseppe Giaccone; Tomohide Tamura; Kazuhiko Nakagawa; Jean-Yves Douillard; Yutaka Nishiwaki; Johan Vansteenkiste; Shinzoh Kudoh; Danny Rischin; Richard Eek; Takeshi Horai; Kazumasa Noda; Ichiro Takata; Egbert Smit; Steven Averbuch; Angela Macleod; Andrea Feyereislova; Rui-Ping Dong; José Baselga
Journal:  J Clin Oncol       Date:  2003-05-14       Impact factor: 44.544

10.  Epidermal growth factor receptor in non-small-cell lung carcinomas: correlation between gene copy number and protein expression and impact on prognosis.

Authors:  Fred R Hirsch; Marileila Varella-Garcia; Paul A Bunn; Michael V Di Maria; Robert Veve; Roy M Bremmes; Anna E Barón; Chan Zeng; Wilbur A Franklin
Journal:  J Clin Oncol       Date:  2003-09-02       Impact factor: 44.544
View more
  10 in total

Review 1.  Genome-based versus gene-based theory of cancer: possible implications for clinical practice.

Authors:  Natasa Todorovic-Rakovic
Journal:  J Biosci       Date:  2011-09       Impact factor: 1.826

2.  Inhibition of ErbB2 by herceptin reduces viability and survival, induces apoptosis and oxidative stress in Calu-3 cell line.

Authors:  Irem Dogan; Ahmet Cumaoglu; Aysel Aricioglu; Abdullah Ekmekci
Journal:  Mol Cell Biochem       Date:  2010-10-10       Impact factor: 3.396

3.  Clinical usefulness of D2-40 in non-small cell lung cancer.

Authors:  Kyung Hoon Min; Seoung Ju Park; Kyung Sun Lee; Sung Ho Hwang; So Ri Kim; Hee Moon; Hyo Jin Han; Myoung Ja Chung; Yong Chul Lee
Journal:  Lung       Date:  2010-11-25       Impact factor: 2.584

Review 4.  Impact of Precision Medicine in Diverse Cancers: A Meta-Analysis of Phase II Clinical Trials.

Authors:  Maria Schwaederle; Melissa Zhao; J Jack Lee; Alexander M Eggermont; Richard L Schilsky; John Mendelsohn; Vladimir Lazar; Razelle Kurzrock
Journal:  J Clin Oncol       Date:  2015-08-24       Impact factor: 44.544

5.  Mad2 checkpoint gene silencing using epidermal growth factor receptor-targeted chitosan nanoparticles in non-small cell lung cancer model.

Authors:  Ana Vanessa Nascimento; Amit Singh; Hassan Bousbaa; Domingos Ferreira; Bruno Sarmento; Mansoor M Amiji
Journal:  Mol Pharm       Date:  2014-09-26       Impact factor: 4.939

6.  Longitudinal Transcriptional Response of Glycosylation-Related Genes, Regulators, and Targets in Cancer Cell Lines Treated With 11 Antitumor Agents.

Authors:  Julia Krushkal; Yingdong Zhao; Curtis Hose; Anne Monks; James H Doroshow; Richard Simon
Journal:  Cancer Inform       Date:  2017-12-15

Review 7.  Is Melatonin the Cornucopia of the 21st Century?

Authors:  Nadia Ferlazzo; Giulia Andolina; Attilio Cannata; Maria Giovanna Costanzo; Valentina Rizzo; Monica Currò; Riccardo Ientile; Daniela Caccamo
Journal:  Antioxidants (Basel)       Date:  2020-11-05

8.  Recurrent squamous cell carcinoma of the skin treated successfully with single agent cetuximab therapy.

Authors:  Selcuk Seber; Aylin Gonultas; Ozlem Ozturk; Tarkan Yetisyigit
Journal:  Onco Targets Ther       Date:  2016-02-25       Impact factor: 4.147

9.  Molecular genomic features associated with in vitro response of the NCI-60 cancer cell line panel to natural products.

Authors:  Julia Krushkal; Simarjeet Negi; Laura M Yee; Jason R Evans; Tanja Grkovic; Alida Palmisano; Jianwen Fang; Hari Sankaran; Lisa M McShane; Yingdong Zhao; Barry R O'Keefe
Journal:  Mol Oncol       Date:  2020-11-24       Impact factor: 7.449

10.  Measurement of Serum EGFR mRNA Expression is a Reliable Predictor of Treatment Response and Survival Outcomes in Non- Small Cell Lung Cancer.

Authors:  Anant Mohan; Ashraf Ansari; Mirza Masroor; Alpana Saxena; R M Pandey; Ashish Upadhyay; Kalpana Luthra; G C Khilnani; Deepali Jain; Rakesh Kumar; Randeep Guleria
Journal:  Asian Pac J Cancer Prev       Date:  2020-11-01
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.